VivoSeq
Other

PIK3CA-Related Overgrowth Spectrum (PROS)

6

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

PIK3CA-related Overgrowth Spectrum (PROS) is an early-stage landscape with 6 programs across 5 companies. The most active players are Novartis, Fresenius Kabi Oncology Ltd., Roche.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

Phase 2Roche logo

Roche

1 program

Phase 2H

Haihe Biopharma Co., Ltd.

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody233%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 86% of 7 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Not yet recruiting1 · 33%

Clinical Trials

Trial Activity

Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Recruiting·Novartis logoNovartis·Phase 2·NCT06997588·104 enrolled
An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.
Not yet recruiting·Novartis logoNovartis·Phase 2·NCT07679269·51 enrolled
A Phase I/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CYH33 (a Selective PI3Kα Inhibitor) in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
Recruiting·HHaihe Biopharma Co., Ltd.·Preclinical·NCT06975618·141 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)